SK Biopharmaceuticals has in-licensed its second radiopharmaceutical – this time from a US-based academic organisation – in a bid to enhance its oncology pipeline. Through its deal with the Wisconsin Alumni Research Foundation (WARF), the South Korean biotech has acquired the institution’s…
Continue reading...